20/20 Biolabs, Inc.
Close on Oct 19, 2026
- Market cap
- $2.81M
- P/E (TTM)
- –
- Dividend yield
- –
About 20/20 Biolabs
Services-Testing Laboratories, SIC 8734
20/20 Biolabs, Inc. develops and commercializes artificial intelligence-powered, laboratory-based blood tests designed for the early detection and prevention of cancers and chronic diseases. The company offers two main diagnostic families under its OneTest brand: OneTest for Cancer, a multi-cancer early detection blood test based primarily on a panel of protein tumor markers, and OneTest for Longevity, which measures inflammatory biomarkers for wellness and longevity applications. In addition to clinical testing, the company operates a shared laboratory accelerator called CLIAx for overseas diagnostic start-ups seeking to enter the United States market, and maintains a legacy product line consisting of the BioCheck field test kit for screening suspicious powders for bioterror agents. Its customer base includes consumers, self-insured employers, and emergency responders such as firefighters.
The company operates a CAP-accredited and CLIA-licensed clinical laboratory located at its headquarters in Gaithersburg, Maryland. All testing operations and administrative functions are conducted from this facility.
Summary of the business section of 20/20 Biolabs's latest annual report, written by StockData.
Company profile
Company
- Legal name
- 20/20 Biolabs, Inc.
- Founded
- 2000
- Headquarters
- Rockville, MD
- Address
- 9430 Key West Avenue, Suite 100 20850
- Phone
- (240) 453-6339
- Employees
- 14, Dec 31, 2025
- Industry
- Services-Testing Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- mckennon, San Diego, California
Stock & identifiers
- Ticker
- AIDX
- Exchange
- Nasdaq
- Shares outstanding
- 13M, Aug 14, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1139685
- CUSIP
- 90138K101
- ISIN
- US90138K1016
- EIN
- 52-2272107
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jonathan M. Cohen | Chief Executive Officer, Director | 1,366,400 |
| Jiming Zhou | Chief Operating Officer | – |
| Alan B. Bergman | Chief Financial Officer | – |
| Ron Baker | Chief Business Officer | – |
| Michael Saul Lebowitz | Chief Scientific Officer | – |
| Richard M. Cohen | Director | 7,700 |
| John G. Compton | Director | 14,335 |
| John Woodson Rollins | Director | 30,275 |
| Michael A. Ross | Director | 31 |
| Prasanth Reddy | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 10, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 22, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 15, 2026 | Late filing | Notification of late filing |
| Feb 13, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 26, 2025 | Name change | Name changed from 20/20 GeneSystems, Inc. to 20/20 Biolabs, Inc. |